Drug reference
Prevention of meningitis due to meningococci groups A, C and W135: in mass immunisation campaigns in the event of an outbreak due to meningococcus A, C or W135 in travellers spending more than 1 month in hyperendemic areas
PDF page 528
Do not administer to patients with history of an allergic reaction to a previous injection of meningococcal vaccine. Vaccination should be postponed in the event of severe acute febrile illness; minor infections are not contra-indications. May cause: mild local reaction, mild fever. Do not mix with other vaccines in the same syringe (inactivation of vaccines). If administered simultaneously with EPI vaccines, use different syringes and injection sites. Pregnancy: no contra-indication Breast-feeding: no contra-indication
PDF page 528
Inactivated bacterial vaccine, polysaccharide Powder for injection in multidose vial, to be dissolved with the entire vial of the diluent supplied by the manufacturer, for SC injection only
PDF page 528
Child from 2 years and adult: 0.5 ml single dose
PDF page 528
Immunity develops 7 to 10 days after injection, and lasts for approximately 3 years.
PDF page 528
Powder: between 2 °C and 8 °C. Diluent: a cold chain is not required for storage. However, at least 12 hours before reconstitution of the vaccine, the diluent must be refrigerated between 2 °C and 8 °C so that the diluent and lyophilised powder are at the same temperature: a temperature difference during reconstitution may reduce vaccine efficacy. Do not freeze. Reconstituted vaccine: between 2 °C and 8 °C, for 6 hours maximum.
PDF pages 528, 529
0.5 ml single dose
PDF page 528
